title: [Efficacy and safety of acute bronchitis treatment in adults--a comparison of Bronchosol® syrup and synthetic preparations with ambroxol. Results of observational study].
abstract: BACKGROUND
  Upper respiratory tract infections (URTI), including acute bronchitis, are the frequent health problems and the most common reason for acute cough in adults. Even though the infections are caused mainly by viruses, and their course is usually not complicated, febrifuges, i.a. mucokinetics, or antitussives are used in the treatment of URTI in order to improve the quality of life and safety of patients.
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of Bronchosol® herbal syrup in comparison to ambroxol preparations in the treatment of acute bronchitis in adult patients.
  
  
  METHODS
  The Bronchosol®/2013 study was a non-interventional, prospective, open-label, observational study. Data from adult patients treated with Bronchosol® syrup for acute bronchitis were collected and compared with data from patients treated for the same condition with ambroxol preparations. The severity of bronchitis symptoms was evaluated with the BSS (Bronchitis Severity Score) scale, and patients'quality of life wasassessed with the VAS (Visual Analogue Scale) scale. Between visits patients conducted self-observations and filled out observation diaries. Moreover, the data on adverse events were collected.
  
  
  RESULTS
  In 87.68% of patients the infections were cured. Most of patients considered the studied drugs to be the agent decreasing the duration of infection and its intensity. The percentage of patients who declared that they had a less intense cough than during earlier infections was higher in the group of patients treated with Bronchosol® syrup in comparison to ambroxol treated patients (60.22% vs. 45.03%). 91.94% of patients treated with Bronchosol® considered this syrup to be very safe; in the ambroxol group such a declaration was made by 76.61% of patients.
  
  
  CONCLUSIONS
  Bronchosol® syrup is an efficient, well-tolerated, and safe drug. Its efficacy in the treatment of acute bronchitis symptoms in adult patients is similar to the efficacy of ambroxol preparations.
authors.forename: Andrzej M
authors.initials: AM
authors.lastname: Fal
authors.forename: Karina
authors.initials: K
authors.lastname: Schönknecht
mesh_terms: D000208:Acute Disease; D000328:Adult; D000551:Ambroxol / Q000627:therapeutic use*; D000996:Antitussive Agents / Q000627:therapeutic use; D001991:Bronchitis / Q000150:complications / Q000188:drug therapy*; D003371:Cough / Q000209:etiology / Q000517:prevention & control*; D005100:Expectorants / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D028321:Plant Preparations / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life
chemical_list: D000996:Antitussive Agents; D005100:Expectorants; D028321:Plant Preparations; D000551:Ambroxol